Vertex Pharmaceuticals is diversifying from its cystic fibrosis dominance into pain and other markets. Check out our ...

Vertex continues to capitalize on its leadership in cystic fibrosis (CF) treatments, where its blockbuster drug Trikafta is ...

A marker linked to inflammation, C-reactive protein, may increase significantly during the follicular phase of the menstrual ...

Vertex’s effort to provide fertility support services to those on government insurance programs who want to take the ...

Bluebird Bio and Xcellbio have entered into an agreement to support the commercialization of sickle cell gene therapy ...

The Department of Health - Abu Dhabi (DoH), the regulator of the healthcare sector in the emirate, has announced the ...

KAFTRIO ® (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor is approved in the European Union for the treatment of cystic fibrosis (CF) in patients aged 2 years and above who have at ...

The past year has been transformative for Vertex, marked by the launch of Casgevy, a groundbreaking treatment for sickle cell disease patients. This one-time, gene-edited cell therapy, developed ...

Patients with genetic disorders such as thalassemia and sickle cell disease will greatly benefit from this revolutionary ... Hisham Hagar, Senior Country Manager at Vertex GCC, said: “We are delighted ...